BCC 2025 | PRE-ACT-01: AI-based risk prediction for RT-induced lymphoedema

Tim Rattay • 13 Mar 2025

BCC 2025

Breast Cancer

PRE-ACT-01

Tim Rattay, MBChB, PhD, FRCS, University of Leicester, Leicester, UK, gives an overview of the PRE-ACT-01 trial, which evaluates an artificial intelligence (AI)-based risk prediction model for arm lymphoedema in patients with breast cancer undergoing regional lymph node irradiation. The trial compares AI-informed treatment decisions to standard care, assessing lymphoedema rates, radiotherapy (RT) modifications, and oncologic outcomes. If successful, the model could enhance shared decision-making, reduce lymphoedema incidence, and refine personalized radiotherapy approaches, potentially influencing clinical practice. This interview took place at the 2025 St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.